Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disitamab Vedotin + Anlotinib in HR-/HER2-low Metastatic Breast Cancer
NCT06000033Phase 2Not yet recruiting
- Sponsor
- Qilu Hospital of Shandong University
- Start
- Aug 2023
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
01
Overview
A Phase 2 trial of disitamab vedotin in breast cancer, sponsored by Qilu Hospital of Shandong University. Planned start Aug 2023; status: not yet recruiting.
02
Drugs
disitamab vedotin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06000033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06000033.